A composition for preventing or treating degenerative brain diseases, comprising hibiscus, rosemary and grape seed extracts as active ingredients

A composition of hibiscus, rosemary, and grape seed extracts addresses the lack of effective treatments for degenerative brain diseases by reducing β-amyloid aggregation and improving memory in Alzheimer's disease models, providing a safe and synergistic therapeutic option.

JP7586413B2Active Publication Date: 2024-11-19POSTECH ACADEMY INDUSTRY FOUNDATION +1

Patent Information

Application Number
JP2022573281
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-05-28
Filing Date
2021-05-28
Publication Date
2024-11-19
Estimated Expiration
2041-05-28

AI Technical Summary

Technical Problem

Current treatments for degenerative brain diseases, particularly Alzheimer's disease, lack effective preventive and therapeutic options, and existing compositions using lactic acid bacteria have limited commercial application.

Method used

A pharmaceutical composition containing hibiscus, rosemary, and grape seed extracts is developed, which can be administered to prevent or treat degenerative brain diseases, improve memory, and enhance cognitive function, with a synergistic effect demonstrated in animal models.

Benefits of technology

The composition effectively reduces β-amyloid aggregation, decreases reactive gliosis, and improves memory and cognitive function in Alzheimer's disease models without cytotoxicity, offering a safe and effective alternative to existing treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007586413000001
    Figure 0007586413000001
  • Figure 0007586413000002
    Figure 0007586413000002
  • Figure 0007586413000003
    Figure 0007586413000003
Patent Text Reader

Abstract

The present invention relates to a composition for preventing or treating degenerative brain diseases, which comprises hibiscus, rosemary, and grape seed extracts as active ingredients. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating degenerative brain diseases, which comprises hibiscus, rosemary, and grape seed extracts as active ingredients; a method for treating degenerative brain diseases using the pharmaceutical composition; a functional food composition for preventing or ameliorating degenerative brain diseases, which comprises the extracts as an active ingredient; a functional food composition for improving memory or cognitive function, which comprises the extracts as an active ingredient; and a feed composition for preventing or ameliorating degenerative brain diseases, which comprises the extracts as an active ingredient. The composition containing the hibiscus, rosemary, and grape seed extracts of the present invention as active ingredients has the efficacy of preventing, treating, or improving degenerative brain diseases, and also has the efficacy of improving memory or cognitive function, and therefore can be used in the development of compositions for treating degenerative brain diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition for preventing or treating degenerative brain diseases, which contains hibiscus, rosemary and grape seed extracts as active ingredients. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating degenerative brain diseases, which contains hibiscus, rosemary and grape seed extracts as active ingredients, a method for preventing or treating degenerative brain diseases using the pharmaceutical composition, a functional food composition for preventing or ameliorating degenerative brain diseases, which contains the extracts as an active ingredient, a functional food composition for improving memory or cognitive function, which contains the extracts as an active ingredient, and a feed composition for preventing or ameliorating degenerative brain diseases, which contains the extracts as an active ingredient. [Background technology]

[0002] As the country rapidly transitions to a modern and aging society, degenerative brain diseases, which are senile diseases, are on the rise, and the incidence of senile dementia in particular is rising. Korea has had the fastest aging rate among OECD countries for the past 40 years, and the number of dementia patients is also increasing. Due to the increase in dementia patients, the socioeconomic costs incurred for dementia treatment have already approached 10 trillion won in 2012, and are predicted to cost 134.6 trillion won by 2050, and the market for dementia treatment drugs is also showing a tendency to increase.

[0003] Dementia is a type of degenerative brain disease characterized by the abnormal aggregation of specific proteins in specific parts of the brain, which causes symptoms such as cognitive impairment, memory loss, and reduced motor skills due to the death of nerve cells. Dementia is classified into diseases according to the cause, but Alzheimer's dementia has the highest incidence rate. The causes of Alzheimer's dementia include amyloid-β peptide aggregates and tau protein aggregates. Amyloid-β peptide aggregates are formed when amyloid precursor proteins are cleaved by β-secretase and γ-secretase due to genetic and environmental factors to form many peptides consisting of 40 or 42 amino acids, but since these peptides have a β-sheet secondary structure, the peptides aggregate and form huge aggregates called plaques. Tau proteins are proteins involved in the structural stabilization of microtubules present in the axons of nerve cells, and when they are hyperphosphorylated, they become tangled with each other. Tau protein aggregates not only destroy the structure of nerve cells but also exhibit cytotoxicity, causing nerve cell death.

[0004] When Aβ peptides and tau protein aggregates are produced in brain tissue, a large amount of reactive oxygen species is generated, causing an inflammatory reaction by microglia. IL-1, TNF-α, PGE2, NO, NOO-, H2O2, etc. are secreted from microglia, promoting the death of surrounding nerve cells. Reactive oxygen species are generated by oxidative stress, which leads to the release of cytochrome C and activation of caspase-3 in mitochondria, causing cell death. In addition to increasing the aggregation of Aβ peptides, it also causes the aggregation of tau protein, which stabilizes microtubules present in nerve cells. When microtubules are destroyed, the axons and dendrites of nerve cells atrophy, causing brain nerve cells to degenerate, and tau protein aggregates and accumulates in the cells, causing disorders in neural signal transduction such as intracellular material transport, leading to cell death.

[0005] Thus, the main symptoms of degenerative brain diseases are caused by an increase in protein aggregates in brain tissue, which induces an inflammatory immune response in brain tissue and spreads to surrounding tissues, and the function of intracellular organelles is disrupted, resulting in cell death, which leads to degeneration of brain tissue.

[0006] Alzheimer's disease, which accounts for roughly half of all cases of dementia in the elderly, currently has no effective treatment for the cause, nor is there any way to prevent it. There are five types of drugs approved by the US Food and Drug Administration (FDA) that are prescribed to Alzheimer's patients, including acetylcholine esterase inhibitors and glutamate receptor inhibitors, but all of these only serve to alleviate symptoms.

[0007] Since drugs must be taken for a long time to treat degenerative brain diseases, it is essential to develop substances with low toxicity and excellent efficacy. Therefore, if natural edible substances with therapeutic and preventive functions are developed, side effects can be minimized.

[0008] On the other hand, Patent Documents 1 and 2 disclose compositions for treating degenerative brain diseases containing lactic acid bacteria or products fermented by lactic acid bacteria, but they are not very effective in treating degenerative brain diseases such as dementia, and there are limitations to their commercial application. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] Korean Patent No. 10-1424547 [Patent Document 2] Korean Patent Publication No. 10-2015-0047687 [Patent Document 3] Korean Patent No. 10-1044433 [Patent Document 4] Korean Patent No. 10-1099021 Summary of the Invention [Problem to be solved by the invention]

[0010] Under these circumstances, the inventors have made extensive efforts to develop an agent for preventing or treating degenerative brain diseases, and as a result have confirmed that a composite extract of hibiscus, rosemary and grape seed has excellent efficacy in preventing and treating degenerative brain diseases, thereby completing the present invention. [Means for solving the problem]

[0011] The present invention aims to provide a pharmaceutical composition for preventing or treating degenerative brain diseases, which comprises hibiscus, rosemary and grape seed extracts as active ingredients.

[0012] Another object of the present invention is to provide a method for preventing or treating a degenerative brain disease, comprising the step of administering the pharmaceutical composition to an individual other than a human.

[0013] A further object of the present invention is to provide a functional food composition for preventing or ameliorating degenerative brain diseases, which comprises hibiscus, rosemary and grape seed extracts as active ingredients.

[0014] Furthermore, the present invention aims to provide a functional food composition for improving memory or cognitive function, which contains hibiscus, rosemary and grape seed extracts as active ingredients.

[0015] A further object of the present invention is to provide a feed composition for preventing or ameliorating degenerative brain diseases, which comprises hibiscus, rosemary and grape seed extracts as active ingredients. Effect of the Invention

[0016] The composition containing the hibiscus, rosemary and grape seed extracts of the present invention as active ingredients has the efficacy of preventing, treating or improving degenerative brain diseases, and also has the efficacy of improving memory or cognitive function, and therefore can be used in the development of compositions for the treatment of degenerative brain diseases. [Brief description of the drawings]

[0017] [Figure 1] FIG. 1 is a schematic diagram showing a method for preparing an extract. [Diagram 2] 1 is a graph showing cell viability in each extract. [Diagram 3] 1 shows diagrams and graphs indicating the presence or absence of genotoxicity in cells in each extract. [Figure 4] 1 is a graph showing the antioxidant efficacy of extracts at various concentrations. [Diagram 5] 1 is a graph showing the inhibitory effect of extracts at various concentrations on intracellular nitrogen production. [Figure 6] FIG. 1A is a schematic diagram showing the procedure of the Y-maze test, and FIG. 1B is a graph showing the evaluation of short-term memory of mice in each group using the Y-maze test. [Figure 7] 1 is a graph showing the measurement of spatial memory ability of Alzheimer's disease model mice by Morris water maze test. [Figure 8] Graphs A and B show the time each group spent on the platform in the Morris water maze test, and graph C shows the total distance traveled by each group of mice in the Morris water maze test. [Figure 9] 1 is a graph showing the synergistic effect of the combined extract in improving memory by measuring short-term memory of each group of mice using a Y-maze test. [Figure 10] 1 is a graph showing the memory improving efficacy of the combined extract at various concentrations. [Figure 11] FIG. 1A is a photograph and a graph showing the degree of β-amyloid aggregate deposition in the hippocampus of a mouse model, and FIG. 1B is a photograph and a graph showing the degree of β-amyloid aggregate deposition in the cerebral cortex of a mouse model. [Figure 12] Photographs and graphs showing the degree of gliosis in the hippocampus of a mouse model are shown in A, and photographs and graphs showing the degree of gliosis in the cerebral cortex of a mouse model are shown in B. [Figure 13]Graph A shows the amount of water-soluble β-amyloid protein in mouse brain tissue, and graph B shows the amount of insoluble amyloid protein in mouse brain tissue. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] These will be described in detail below. Note that each description and embodiment disclosed in the present invention is also applicable to other descriptions and embodiments. In other words, all combinations of various elements disclosed in the present invention are included in the present invention. In addition, the present invention is not limited to the following specific description.

[0019] To achieve the above object, one aspect of the present invention provides a pharmaceutical composition for preventing or treating degenerative brain diseases, comprising hibiscus, rosemary and grape seed extracts as active ingredients.

[0020] Another aspect of the present invention provides a pharmaceutical composition for improving memory or cognitive function comprising hibiscus, rosemary and grape seed extracts as active ingredients.

[0021] The present invention also provides the use of hibiscus, rosemary and grape seed extracts in the treatment of degenerative brain diseases.

[0022] Specifically, the extract is a 2:1:1 ratio of hibiscus, rosemary and grape seed extract, but is not limited thereto.

[0023] The "hibiscus (Hibiscus sabdariffa L.)" in the present invention is a plant belonging to the Malvaceae family, which grows mainly in tropical and subtropical regions. Its thick, red cup-shaped calyx is consumed not only as a cold drink but also as tea, and is effective against high blood pressure, fever, liver disease, inflammation, gallstones, and obesity. Hibiscus extract has been reported to have the effect of reducing total lipids, cholesterol, and triglycerides, and is known to have excellent preventive, antioxidant, and anticancer effects against dyslipidemia.

[0024] "Rosmarinus officinalis" in the present invention is native to the Mediterranean Sea, but is now cultivated in California, Russia, the Middle East, England, France, Spain, Portugal, Yugoslavia, Morocco, etc. Rosemary is a leafy shrub that grows to 2 meters, with needle-like gray-green leaves and pale blue flowers that give off a strong aromatic scent.

[0025] In the present invention, "grape seeds" refers to grape seeds, and proanthocyanidins in grape seeds have antiviral, antibacterial, anti-inflammatory, and anti-allergic functions. It is known that grape seed extracts are effective in the human body for about three days, and their effectiveness is 20 times that of vitamin C and 50 times that of vitamin E. In addition, there are also reports in the literature on their excellent preventive and therapeutic effects against rheumatoid arthritis and osteoarthritis (Patent Documents 3 and 4).

[0026] In the present invention, the term "extract" refers to a substance obtained by extracting a specific substance, and specifically includes the extract itself and any form of extract that can be formed using the extract, such as the extract obtained by the extraction process, a diluted solution or concentrated solution of the extract, a dried product obtained by drying the extract, a crude product or purified product of the extract, or a mixture thereof.

[0027] The extraction method is not particularly limited, and can be extracted by a method commonly used in the art. The extraction method includes, for example, solvent extraction, ultrasonic extraction, filtration, reflux extraction, etc., but is not limited thereto, and these may be used alone or in combination of two or more methods.

[0028] In the present invention, the type of extraction solvent used for extraction is not particularly limited, and any solvent known in the art can be used. The extraction solvent can be, for example, water, alcohol having 1 to 4 carbon atoms, or a mixture thereof, but is not limited thereto, and these can be used alone or in combination of two or more. Specifically, the extraction solvent can be hot water.

[0029] In the present invention, the term "composite extract" refers to an extract in which two or more extracts are combined into one.

[0030] The composite extract of the present invention is a combination of two or more extracts selected from the group consisting of hibiscus, rosemary, and grape seed, or an extract of a mixture of two or more substances selected from the group, but is not limited thereto.

[0031] The preventive, ameliorative or therapeutic efficacy of the hibiscus, rosemary and grape seed complex extract against degenerative brain diseases was not known and was elucidated for the first time by the present inventors.

[0032] The "neurodegenerative disorders" in the present invention refer to diseases in which degenerative changes appear in nerve cells in the central nervous system, causing various symptoms. Representative degenerative brain diseases include Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, olivopontocerebellar atrophy (OPCA), Shy-Drager syndrome, striatonigral degeneration, Huntington's disease, amyotrophic lateral sclerosis (ALS), essential tremor, cortico-basal ganglionic degeneration, and cerebellar atrophy (CAAD). These include diffuse Lewy body disease, amyotrophic lateral sclerosis / Parkinson-ALS-dementia complex of Guam, and Pick's disease.

[0033] Specifically, the degenerative brain disease of the present invention may be caused by aggregation of soluble or insoluble β-amyloid (Aβ) protein, and more specifically, may be selected from the group consisting of dementia, Alzheimer's disease, Huntington's disease, Parkinson's disease, multiple system atrophy, multiple sclerosis, tauopathies, brain tumors, Pick's disease, and Creutzfeldt-Jakob disease.

[0034] In the present invention, "Alzheimer's disease" is a degenerative brain disease, a typical disease that causes dementia mainly in the elderly. This disease is characterized by the accumulation of β-amyloid (Aβ) and the formation of paired helical filaments (PHFs), which are mostly composed of hyperphosphorylated tau protein. It is known that extracellular β-amyloid deposition and intracellular hyperphosphorylated tau protein throughout the brain cause neuronal death, which is a disease that leads to gradual memory impairment, cognitive decline, changes in personal personality, etc. In the present invention, Alzheimer's disease is used in a sense that includes Alzheimer's dementia.

[0035] In one embodiment of the present invention, the cytotoxicity of hibiscus, rosemary and grape seed extracts was confirmed (Figures 2 and 3), their antioxidant efficacy (Figure 4) and NO inhibitory activity (Figure 5). The memory improving efficacy of the extracts was confirmed by a Y-maze test and Morris water test using Alzheimer's disease model mice (Figures 6 to 9). Furthermore, it was confirmed that administration of the composite extract of the present invention, compared with single extracts, showed a concentration-dependent synergistic effect of improving memory decline by the combination of extracts (Figure 10). The levels of β-amyloid aggregation and reactive gliosis of astrocytes were analyzed by immunohistochemistry and ELISA analysis (Figures 11 to 13), confirming that the extract of the present invention has no cytotoxicity and is harmless, and has memory improving efficacy by reducing β-amyloid aggregation.

[0036] According to the examples of the present invention, it was confirmed that administration of the combined extract restored memory ability to a level equivalent to that of the normal control group, and that although the efficacy of rosemary or grape seed extracts alone was rather reduced, a synergistic effect was observed when these were combined.

[0037] The pharmaceutical composition of the present invention may further comprise a pharma- ceutically acceptable carrier, excipient or diluent, said carrier may be a non-naturally occurring carrier.

[0038] More specifically, the carriers, excipients and diluents contained in the pharmaceutical composition include lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, polycaprolactone, polylactic acid, poly-L-lactic acid, mineral oil and the like.

[0039] The pharmaceutical compositions are formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions by conventional methods, and examples of the carrier form include various amorphous carriers, microspheres, nanofibers, etc.

[0040] When the formulation is made, it may be prepared using a diluent or excipient that is commonly used, such as a filler, extender, binder, wetting agent, disintegrant, or surfactant.

[0041] Oral solid preparations include tablets, pills, powders, granules, capsules, etc., and these solid preparations may be prepared by mixing the extract and its fractions with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to the usual excipients, lubricants such as magnesium stearate and talc are also used.

[0042] Oral liquid preparations include suspensions, liquid preparations for internal use, emulsions, syrups, etc., and in addition to the commonly used diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, flavorings, preservatives, etc. are used.

[0043] Examples of parenteral preparations include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.

[0044] The contents of hibiscus, rosemary and grape seed extracts contained in the pharmaceutical composition of the present invention are not particularly limited.

[0045] In the present invention, "prevention" refers to any action of suppressing or delaying the onset of a disease by the pharmaceutical composition according to the present invention.

[0046] In the present invention, "treatment" refers to any action of improving or beneficially altering the symptoms of an individual suffering from a disease by using the pharmaceutical composition.

[0047] In the present invention, the term "cognitive function" refers to a series of activities, techniques, internal control processes, etc. that occur in the brain to obtain and process external information.

[0048] In the present invention, "amelioration" means using the extract of the present invention to suppress or inhibit the symptoms of a disease, or to alleviate the symptoms of an already developed disease.

[0049] The pharmaceutical composition of the present invention may be a composition for inhibiting aggregation of water-soluble or insoluble β-amyloid (Aβ) protein.

[0050] In the present invention, "β-amyloid" is also called amyloid β, which is the main component of amyloid plaques found in the brains of Alzheimer's disease patients and refers to a 36-43 amino acid peptide that is critically involved in Alzheimer's disease.

[0051] In the present invention, "aggregation" refers to phase separation from a liquid phase into a non-dispersed phase due to the attractive force of colloidal particles dispersed in a solution.

[0052] In order to achieve the above-mentioned object, yet another aspect of the present invention provides a method for preventing or treating a degenerative brain disease, comprising the step of administering to an individual other than a human a composition containing hibiscus, rosemary and grape seed extracts as active ingredients.

[0053] Here, the terms "hibiscus", "rosemary", "grape seed", "degenerative brain disease", "prevention" and "treatment" are as described above.

[0054] "Administering" in the present invention means introducing the composition of the present invention into a patient by any suitable method, and the route of administration of said composition may be any common route that delivers the composition to the target tissue, including, but not limited to, intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, oral, topical, and intranasal administration.

[0055] The composition of the present invention may be administered daily or intermittently, and may be administered once a day or in two or three separate doses. It may be used alone or in combination with other drug treatments. It is important to administer an amount that provides maximum efficacy with minimal side effects while taking into account all of the above factors, and this can be easily determined by those skilled in the art.

[0056] In the present invention, an "individual" refers to any animal, such as a rat, mouse, livestock, etc., that has or is at risk of developing a degenerative brain disease.

[0057] In order to achieve the above object, yet another aspect of the present invention provides a functional food composition for preventing or ameliorating degenerative brain diseases, comprising hibiscus, rosemary and grape seed extracts as active ingredients.

[0058] In order to achieve the above object, yet another aspect of the present invention provides a functional food composition for improving memory or cognitive function, comprising hibiscus, rosemary and grape seed extracts as active ingredients.

[0059] Here, the terms "hibiscus", "rosemary", "grape seed", "degenerative brain disease", "prevention", "improvement" and "cognitive function" are as described above.

[0060] The hibiscus, rosemary and grape seed extracts according to the present invention exhibit excellent efficacy in improving memory and cognitive function, and therefore may be included in a food composition for the purpose of preventing or improving degenerative brain diseases. Since the food composition can be ingested on a daily basis, it is expected to be highly effective in preventing or improving degenerative brain diseases.

[0061] In the present invention, "functional food" refers to food manufactured and processed using raw materials or ingredients that have useful functions for the human body according to the Functional Food Law No. 6727, and "functional" refers to regulating nutrients for the structure and function of the human body or providing useful effects for health purposes such as physiological actions. Meanwhile, health food refers to food that has more active health maintenance and promotion effects than general foods, and dietary supplement refers to food for the purpose of supplementing health, but in some cases, functional food, health food, and dietary supplement are used interchangeably.

[0062] The hibiscus, rosemary and grape seed extracts of the present invention may be added as is or may be used together with other foods or food ingredients, and may be used appropriately in the usual manner.

[0063] The food of the present invention can be produced by a method commonly used in the art, and can be produced by adding raw materials and ingredients commonly added in the art. Specifically, the food composition may further contain a physiologically acceptable carrier, but the type of carrier is not particularly limited, and any carrier commonly used in the art can be used. In addition, the food composition may contain food additives such as preservatives, bactericides, antioxidants, colorants, colorants, bleaching agents, seasonings, sweeteners, flavors, leavening agents, strengthening agents, emulsifiers, thickeners, coating agents, gum bases, foam inhibitors, solvents, and improvers. The additives are selected according to the type of food and used in appropriate amounts.

[0064] Furthermore, the dosage form of the food may be any dosage form that is recognized as food. The food composition of the present invention can be manufactured into various dosage forms, and unlike general medicines, it is made from food as a raw material, so it has the advantage of having no side effects that may occur when taking medicines for a long period of time, and is highly portable, so the food of the present invention can be taken as an adjuvant to promote liver regeneration.

[0065] The hibiscus, rosemary and grape seed extracts of the present invention may be contained in any weight percent in the food composition as long as they are effective in preventing or improving degenerative brain diseases or improving memory / cognitive function. Specifically, they may be contained in an amount of 0.00001 to 100 weight percent or 0.01 to 80 weight percent based on the total weight of the food composition, but are not limited thereto. For long-term intake for health and hygiene purposes, the content may be below the above range, and there is no problem in terms of safety, so the active ingredient may be used in an amount above the above range.

[0066] In order to achieve the above object, in yet another aspect, the present invention provides a feed composition for preventing or ameliorating degenerative brain diseases, comprising hibiscus, rosemary and grape seed extracts as active ingredients.

[0067] Here, the terms "hibiscus", "rosemary", "grape seed", "degenerative brain disease", "prevention" and "amelioration" are as described above.

[0068] By "feed" in the present invention is meant any natural or artificial diet, meal or the like, or components of such a meal, intended or suitable for consumption, ingestion and digestion by an animal.

[0069] The type of the feed is not particularly limited, and feeds commonly used in the technical field can be used. Examples of the feed include vegetable feeds such as grains, roots and fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, meals, and grain by-products, and animal feeds such as proteins, inorganic substances, oils and fats, minerals, single-cell proteins, animal plankton, and food and drink, but are not limited thereto. These may be used alone or in combination of two or more. EXAMPLES

[0070] The present invention will be described in more detail below with reference to examples. However, these examples are merely illustrative of the present invention and are not intended to limit the present invention.

[0071] Example 1 Preparation of extracts To prepare the hibiscus, rosemary and grape seed extracts, each plant was extracted with 80% ethyl alcohol at 37°C for 24 hours, and the extraction was repeated three times. The hibiscus, rosemary and grape seed extracts were mixed in a 2:1:1 ratio to prepare a composite extract (Figure 1).

[0072] Example 2 Toxicity of the extract The cytotoxicity and genotoxicity of the individual and combined extracts prepared in Example 1 were confirmed. Specifically, the hibiscus, rosemary or grape seed extract alone and the composite extract of the present invention were adjusted to concentrations of 0 to 1000 ppm, and used to treat the RAW264.7 cell line and the BV-2 cell line, and the toxicity was measured by an MTT experiment. As a result, as shown in Figure 2, it was confirmed that rosemary extract alone rapidly exhibited cytotoxicity at a concentration of 250 ppm, whereas the cell viability was not reduced even at a high concentration of 1000 ppm in the case of the combined extract.

[0073] To examine the effect of the composite extract on genotoxicity, a comet assay was performed using 500 μM etoposide as a positive control. As a result, as shown in Figure 3, in the positive control group, comet tails indicating genotoxicity were observed around the cells, but in the composite extract, no comet tails indicating genotoxicity appeared even at a concentration of 1000 ppm.

[0074] Therefore, it was confirmed that the complex extract of the present invention has no cytotoxicity or genotoxicity.

[0075] Example 3 Antioxidant Efficacy of Complex Extracts To confirm the antioxidant efficacy of the complex extract of the present invention, an in vitro DPPH assay was performed. More specifically, the composite extract prepared in Example 1 was prepared at different concentrations and then reacted with DPPH (2,2-diphenyl-1-picrylhydrazyl) reagent. DPPH is a purple-colored compound that turns yellow when reacted with a substance with antioxidant properties due to reduction. Antioxidant efficacy can be measured based on this principle. Here, ascorbic acid was used as a positive control. As a result, as shown in FIG. 4, the complex extract of the present invention was confirmed to have significant antioxidant effects.

[0076] Example 4 Determination of NO inhibitory activity of the composite extracts When an inflammatory response occurs in the body, NF- K The B signal transduction process increases the expression of iNOS, which in turn increases the production of its product, NO (nitric oxide). The amount of NO generated during inflammatory reactions can be measured using the Griess assay, and to measure the NO production inhibitory activity of the extract, the RAW264.7 cell line was treated with the composite extract of the present invention prepared as described above. When an experiment was carried out to measure the NO production inhibitory activity, it was found that the composite extract of the present invention inhibited NO production in a concentration-dependent manner (Figure 5).

[0077] Example 5 Efficacy of improving memory in Alzheimer's disease model mice Example 5-1: Y-maze test The memory improving efficacy of hibiscus, rosemary and grape seed extracts was confirmed by a Y-maze test in Alzheimer's disease model mice. More specifically, 7-week-old 5XFAD Alzheimer's disease model mice were orally administered the composite extract of the present invention at a concentration of 200mg / kg for 14 weeks (Fig. 6A).After this administration, the short-term memory of the mice was tested by a Y-maze test. As a result, as shown in FIG. 6, the memory ability of the Alzheimer's disease model mice (Y-maze alteration = 51.88%) was reduced compared to that of the normal control group (Y-maze alteration = 63.01%), whereas in the group administered with the composite extract of the present invention, it was confirmed that the memory decline caused by the induction of Alzheimer's disease was improved (Y-maze alteration = 61.28%) (FIG. 6B). Therefore, it was confirmed that the complex extract of the present invention has the effect of improving memory loss caused by Alzheimer's disease.

[0078] Example 5-2: Water maze test The memory improving effect of the composite extract of the present invention was confirmed by a water maze experiment using Alzheimer's disease model mice. More specifically, 7-week-old 5XFAD Alzheimer's disease model mice were orally administered the composite extract of the present invention at a concentration of 200 mg / kg for 14 weeks (Figure 6A). After this administration, an experiment was performed using a Morris water maze to determine whether the Alzheimer's disease model mice remembered the platform, and the learning ability of remembering the platform position was measured after 5 days of training. As a result, as shown in Figure 7, it was confirmed that the learning ability of the Alzheimer's disease model mouse (red) was the most impaired, while the learning ability of the dementia model mouse (blue) administered with the complex extract of the present invention was greatly improved.

[0079] As shown in Figure 8, the platform was removed on the sixth day, and the frequency with which the mice stayed in the area where the platform had been located was measured. It was confirmed that the frequency with which the mice stayed in the area where the platform had been located was higher in the Alzheimer's disease model mice group administered with the extract of the present invention than in the control group (Figure 8A and B). On the other hand, it was confirmed that the total distance traveled by each mouse group was similar (Figure 8C). Therefore, it was confirmed that administration of the composite extract of the present invention alleviates the symptoms of Alzheimer's dementia and improves memory without affecting mobility.

[0080] Example 6 Verification of the synergistic effect of the combined extract on improving memory using Alzheimer's disease model mice In order to confirm the synergistic effect of the composite extract of the present invention in improving memory, a Y-maze test was carried out on Alzheimer's disease model mice. The specific experimental method was the same as in Example 5-1. As a result, as shown in Figure 9, the memory ability of the Alzheimer's disease model mice (Y-maze alteration = 51.88%) was lower than that of the normal control group (Y-maze alteration = 63.01%). When each single extract and their combined extract were administered, a significant improvement in memory was observed in the group administered with hibiscus single extract (Y-maze alteration = 57.76%), and it was confirmed that the memory ability of the group administered with the combined extract was improved to the level of the normal control group (Y-maze alteration = 61.28%) (Figure 9).

[0081] The concentrations of each extract in the composite extract were 100mg / kg of hibiscus extract, 50mg / kg of grape seed extract, and 50mg / kg of rosemary extract, which were lower than the doses of the individual extracts (200mg / kg each), but showed excellent improvement in memory ability. Also, although the efficacy of rosemary or grape seed extract alone in improving memory ability was rather reduced, it was confirmed that there was a synergistic effect when they were combined.

[0082] Example 7 Memory improvement efficacy of various concentrations of the combined extract in Alzheimer's disease model mice To investigate the optimal concentration of the combined extract for memory improvement, the combined extract was orally administered to 7-week-old 5XFAD Alzheimer's disease model mice at concentrations of 100, 200, and 400 mg / kg for 14 weeks. After administration, the short-term memory of the mice was tested using a Y-maze test. As a result, as shown in FIG. 10, it was found that the higher the concentration of the composite extract, the more the memory ability improved to the normal level.

[0083] Example 8 Brain tissue analysis of Alzheimer's disease model mice Example 8-1: Immunohistochemical analysis The degree of β-amyloid aggregation and reactive gliosis of the composite extract of the present invention were analyzed by immunohistochemistry of brain tissues from Alzheimer's disease model mice. More specifically, brain tissue was observed using 6E10 antibody by immunohistochemistry, and the level of reactive gliosis was measured, since a decrease in β-amyloid aggregates leads to a decrease in the inflammatory response activity of surrounding astrocytes. As a result, as shown in Figure 11, it was confirmed that beta-amyloid aggregation was reduced to approximately one-third and approximately one-quarter, respectively, in the hippocampus and cerebral cortex of the Alzheimer's disease model mouse group administered the composite extract of the present invention, compared to the Alzheimer's disease model mouse group not administered the extract (Figures 11A and 11B).

[0084] In addition, because a reduction in β-amyloid aggregates reduces the activity of surrounding astrocytes due to inflammatory responses, the level of reactive gliosis in surrounding astrocytes was analyzed. More specifically, the brains of Alzheimer's disease model mice were removed and sliced, and then analyzed using an antibody against GFAP, an astrocyte-specific protein (Figures 12A and 12B). As a result, as shown in FIG. 12, it was confirmed that administration of the composite extract of the present invention significantly reduced the antibody response indicating the level of reactive gliosis in surrounding astrocytes.

[0085] Example 8-2: ELISA analysis To confirm the changes in soluble and insoluble β-amyloid proteins, they were analyzed by ELISA experiments. As a result, as shown in FIG. 13, it was confirmed that the amounts of water-soluble and insoluble β-amyloid proteins were reduced.

[0086] Therefore, it was confirmed that the complex extract of the present invention has the efficacy of preventing or treating degenerative brain diseases such as Alzheimer's disease, since it reduced β-amyloid protein.

[0087] From the above description, a person skilled in the art to which the present invention pertains will understand that the present invention can be implemented in other specific forms without changing its technical ideas or essential features. It should be understood that the above examples are merely illustrative and not limiting. The present invention should be interpreted as including all modifications and alterations derived from the meaning and scope of the claims and their equivalent concepts, rather than the specification.

Claims

1. A pharmaceutical composition for preventing or treating a degenerative brain disease, comprising an ethanol extract of hibiscus (Hibiscus sabdariffa L.), rosemary and grape seed as active ingredients, wherein the degenerative brain disease is dementia or Alzheimer's disease.

2. 2. The pharmaceutical composition for preventing or treating degenerative brain diseases according to claim 1, wherein the weight ratio of the hibiscus (Hibiscus sabdariffa L.), rosemary and grape seed ethanol extract is 2:1:

1.

3. The pharmaceutical composition for preventing or treating a degenerative brain disease according to claim 1 , wherein the degenerative brain disease is caused by aggregation of soluble or insoluble β-amyloid (Aβ) protein.

4. The pharmaceutical composition for preventing or treating degenerative brain diseases according to claim 1, wherein the ethanol extract of Hibiscus (Hibiscus sabdariffa L.), rosemary and grape seed exerts effects of antioxidant, inhibiting NO production, improving memory, reducing β-amyloid aggregates, reducing gliosis level and reducing β-amyloid protein amount.

5. A method for preventing or treating a degenerative brain disease, comprising the step of administering to an individual other than a human the pharmaceutical composition according to any one of claims 1 to 4.

6. A functional food composition for preventing or improving a degenerative brain disease, comprising hibiscus (Hibiscus sabdariffa L.), rosemary and grape seed ethanol extract as active ingredients, wherein the degenerative brain disease is dementia or Alzheimer's disease.

7. A functional food composition for improving memory or cognitive function comprising Hibiscus (Hibiscus sabdariffa L.), Rosemary and Grape seed ethanol extract as active ingredients, wherein said improvement is in dementia or Alzheimer's disease.

8. A feed composition for preventing or improving a degenerative brain disease, comprising hibiscus (Hibiscus sabdariffa L.), rosemary and grape seed ethanol extract as active ingredients, wherein the degenerative brain disease is dementia or Alzheimer's disease.

Citation Information

Patent Citations

  • Antibacteria itching-relieving traditional Chinese medicine composition and application thereof

    CN110141640A

  • Melanin generation inhibitor consisting of n-acetylthyrosine derivative as active ingredient and application of the same to skin preparation for external use and bath agent

    JP1997323915A

  • Skin care composition and skin care method

    JP2018531976A

  • Process for preparing Vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same

    KR101044433B1

  • Pharmaceutical composition for preventing or treating osteoarthritis comprising Vitis vinifera pip extract

    KR101099021B1

Cited By

  • Composition derived from rosemary for pain relief or peripheral neuropathy relief.

    JP2026169625A